X4 Pharmaceuticals Inc (NASDAQ: XFOR) Surprises The Bears, Looks Good Going Forward

In the last trading session, 4.8 million shares of the X4 Pharmaceuticals Inc (NASDAQ:XFOR) were traded, and its beta was 0.37. Most recently the company’s share price was $0.37, and it changed around $0.0 or -0.57% from the last close, which brings the market valuation of the company to $62.76M. XFOR currently trades at a discount to its 52-week high of $1.60, offering almost -332.43% off that amount. The share price’s 52-week low was $0.26, which indicates that the current value has risen by an impressive 29.73% since then. We note from X4 Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 8.7 million shares, with the 3-month average coming to 2.21 million.

X4 Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.33. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended XFOR as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. X4 Pharmaceuticals Inc is expected to report earnings per share of -0.16 for the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

X4 Pharmaceuticals Inc (NASDAQ:XFOR) trade information

Instantly XFOR has showed a red trend with a performance of -0.57% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.5175 on recent trading dayincreased the stock’s daily price by 28.5%. The company’s shares are currently down -56.11% year-to-date, but still down -37.85% over the last five days. On the other hand, X4 Pharmaceuticals Inc (NASDAQ:XFOR) is -25.81% down in the 30-day period. We can see from the shorts that 11.42 million shares have been sold at a short interest cover period of 8.64 day(s).

The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 87.67% from its current value. Analyst projections state that XFOR is forecast to be at a low of $3 and a high of $5.

X4 Pharmaceuticals Inc (XFOR) estimates and forecasts

X4 Pharmaceuticals Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -58.96 percent over the past six months and at a 57.89% annual growth rate that is well above the industry average of 17.80%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -57.50% in revenue this quarter, and will report an increase of 43.59% in the next quarter.

Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 1.02M in revenue for the current quarter. 3 analysts expect X4 Pharmaceuticals Inc to make 2.53M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at ∞%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 73.95%.

XFOR Dividends

X4 Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in December.

X4 Pharmaceuticals Inc (NASDAQ:XFOR)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 1.15% of X4 Pharmaceuticals Inc shares, and 67.66% of them are in the hands of institutional investors. The stock currently has a share float of 68.45%. X4 Pharmaceuticals Inc stock is held by 126.0 institutions, with BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC being the largest institutional investor. By 2024-06-30, it held 8.4582% of the shares, which is about 16.92 million shares worth $9.81 million.

NEA MANAGEMENT COMPANY, LLC, with 7.4937% or 14.99 million shares worth $8.69 million as of 2024-06-30, holds the second largest percentage of outstanding shares.